new_0222_0431|ABOS|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|sga_expense|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return|price_next_month|price_second_month
new_0222_0431|ABOS|1|Acumen Pharmaceuticals Inc Total Current Assets (Quarterly) (USD)|Acumen Pharmaceuticals Inc Cash and Short Term Investments (Quarterly) (USD)|Acumen Pharmaceuticals Inc Inventories (Quarterly) (USD)|Acumen Pharmaceuticals Inc Net PP&E (Quarterly) (USD)|Acumen Pharmaceuticals Inc Goodwill and Intangibles (Quarterly) (USD)|Acumen Pharmaceuticals Inc Total Liabilities (Quarterly) (USD)|Acumen Pharmaceuticals Inc Total Current Liabilities (Quarterly) (USD)|Acumen Pharmaceuticals Inc Total Long Term Liabilities (Quarterly) (USD)|Acumen Pharmaceuticals Inc Total Deposits (Quarterly) (USD)|Acumen Pharmaceuticals Inc Book Value (Quarterly) (USD)|Acumen Pharmaceuticals Inc Retained Earnings (Quarterly) (USD)|Acumen Pharmaceuticals Inc Treasury Stock (Quarterly) (USD)|Acumen Pharmaceuticals Inc EV to Revenues|Acumen Pharmaceuticals Inc EV to Earnings|Acumen Pharmaceuticals Inc EV to Free Cash Flow|Acumen Pharmaceuticals Inc EV to Assets (Quarterly)|Acumen Pharmaceuticals Inc PS Ratio|Acumen Pharmaceuticals Inc PE Ratio|Acumen Pharmaceuticals Inc Price to Book Value|Acumen Pharmaceuticals Inc PEG Ratio|Acumen Pharmaceuticals Inc Debt to Equity Ratio|Acumen Pharmaceuticals Inc Dividend Yield|Acumen Pharmaceuticals Inc Shareholder Yield (TTM)|Acumen Pharmaceuticals Inc Percent of Shares Outstanding Short|Acumen Pharmaceuticals Inc Total Receivables (Quarterly) (USD)|Acumen Pharmaceuticals Inc Total Payables (Quarterly) (USD)|Acumen Pharmaceuticals Inc Total Capital Stock (Quarterly) (USD)|Acumen Pharmaceuticals Inc Return on Invested Capital|Acumen Pharmaceuticals Inc Quality Ratio Score|Acumen Pharmaceuticals Inc Momentum Score|Acumen Pharmaceuticals Inc Beta (1Y)|Acumen Pharmaceuticals Inc Sustainable Growth Rate (TTM)|Acumen Pharmaceuticals Inc Institutional Investor Ownership Percentage|Acumen Pharmaceuticals Inc Average Diluted Shares Outstanding (Quarterly)|Acumen Pharmaceuticals Inc Total Employees (Annual)|Acumen Pharmaceuticals Inc EPS Diluted (Quarterly) (USD)|Acumen Pharmaceuticals Inc Shares Outstanding|Acumen Pharmaceuticals Inc Repurchase of Capital Stock (Quarterly) (USD)|Acumen Pharmaceuticals Inc Ordinary Shares Number (Quarterly)|Acumen Pharmaceuticals Inc Payout Ratio|Acumen Pharmaceuticals Inc Quick Ratio (Quarterly)|Acumen Pharmaceuticals Inc Normalized Diluted EPS (Quarterly) (USD)|Acumen Pharmaceuticals Inc Stock Buybacks (Quarterly) (USD)|Acumen Pharmaceuticals Inc Effective Tax Rate (TTM)|Acumen Pharmaceuticals Inc Return on Equity|Acumen Pharmaceuticals Inc Net Income (TTM) (USD)|Acumen Pharmaceuticals Inc Revenue (TTM) (USD)|Acumen Pharmaceuticals Inc Dividend Per Share (Quarterly) (USD)|Acumen Pharmaceuticals Inc Revenue (Quarterly) (USD)|Acumen Pharmaceuticals Inc Gross Profit (Quarterly) (USD)|Acumen Pharmaceuticals Inc SG&A Expense (Quarterly) (USD)|Acumen Pharmaceuticals Inc Pre-Tax Income (Quarterly) (USD)|Acumen Pharmaceuticals Inc Net Income (Quarterly) (USD)|Acumen Pharmaceuticals Inc Net Interest Income (Quarterly) (USD)|Acumen Pharmaceuticals Inc Price (USD)|Acumen Pharmaceuticals Inc Total Return Price (USD)|Acumen Pharmaceuticals Inc Enterprise Value (USD)|Acumen Pharmaceuticals Inc 30-Day Average Daily Volume|Acumen Pharmaceuticals Inc 1 Year Price Returns (Daily)||
new_0222_0431|ABOS|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric||
new_0222_0431|ABOS|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|quarterly||
new_0222_0431|ABOS|5|91|91||92||91|91|91||91|91||1.44375||1.44375||1.44099378882||1.4387755102|||1.44375||15.3846153846|91|91|91||||||30.6666666667|91.3333333333||91.3333333333|28.8||91|||91.3333333333|91.25|||91|||91.6666666667||91.3333333333|91.3333333333|91.3333333333|91.3333333333|1.44099378882|1.44099378882|1.44375|1.4427480916|||
new_0222_0431|ABOS|6|3|3||1||3|3|3||3|3||160||160||161||98|||160||13|3|3|3||||||6|6||6|5||3|||6|4|||3|||3||6|6|6|6|161|161|160|131|||
new_0222_0431|ABOS|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily||
new_0222_0431|ABOS|202003||||||||||||||||||||||||||||||||||28.6518||-0.0714||||||-0.0714|||||||0.226||0.222|-2.045|-2.045|0.001|||||||
new_0222_0431|ABOS|202006||||||||||||||||||||||||||||||||||28.6518||-0.071||||||-0.071|||||||0.151||0.259|-2.035|-2.035||||||||
new_0222_0431|ABOS|202009||||||||||||||||||||||||||||||||||28.6518||-0.0869||||||-0.0869|||||||0.73||0.226|-2.49|-2.49||||||||
new_0222_0431|ABOS|202012|44.429|43.777||||63.02|6.367|56.653||-18.591|-26.965||||||||||||||0.109|0.531||||||||28.6518||-0.0468|||38.6518||6.8927|-0.0264||||-7.325|1.436||0.329||0.644|-0.755|-0.755||||||||
new_0222_0431|ABOS|202103|42.103|41.407||||87.835|31.182|56.653||-45.462|-53.962||||||||||||||0.109|0.918||||||||28.6518|7|-0.13|||38.6518|||0.6803||||-32.277|||||1.215|-26.997|-26.997|0.004|||||||
new_0222_0431|ABOS|202106|70.572|68.812||0.006||179.022|4.518|174.504||-106.079|-115.32||384.9149||-51.3029||335.8146|||||||0.0791|0.109|2.907|||||||29.1873|38.6518||-1.659|36.9851||38.6518|||-0.16||||-91.6|||||1.187|-61.358|-61.358|0.004|15.48|15.48|552.7379|160434.4||17.92|
new_0222_0431|ABOS|202109|204.913|199.964||0.013||1.489|1.489|||233.36|-119.222||279.5436|-54.802|-23.3672|9.0352|347.2386||2.5771|||||1.6751|0.109|0.382|0.004||||||77.1977|38.2666||-0.1|40.4703||40.4703|||-0.1|-168.559|||-93.012|||||2.135|-3.902|-3.902|0.014|14.86|14.86|401.4247|263622.0667||14.05|7.9
new_0222_0431|ABOS|202112|||||||||||||51.2641||-4.2852||157.9632||1.1723|||||2.487|||||||||75.082||||||||||||||||||||||6.76|6.76|73.6152|147303.1667||5.12|5.71